Evox Therapeutics, an exosome therapeutics company, announced it has expanded into a new laboratory and office space at the Oxford Science Park, to enhance its research and development (R&D) capabilities and to facilitate its growth.
Following its inception in 2016, Evox has continued to advance its groundbreaking exosome research. This expansion reflects the growing interest and demand in the exosome based biotherapeutics field and will provide access to the R&D facilities and equipment needed to accelerate the company’s extension.
Dr Antonin de Fougerolles, CEO of Evox, said: “We are pleased to be moving into our new, state-of-the-art facilities at the Oxford Science Park. This expansion will accommodate our increase in R&D and expanding pre-clinical pipeline of exosome biotherapeutics.”
“Our research stems from the innovative work carried out at the University of Oxford; therefore we look forward to the opportunities provided by this expansion to continue to attract talented new employees in the Oxford region.”
As part of the move, Evox is expecting to create more than a dozen new job opportunities in the area.
The new 5800 sq. ft space significantly increases the company’s overall footprint and includes state-of-the-art laboratories, providing cleanroom capabilities and a tissue culture / process development laboratory suitable to prepare material for pre-clinical studies.
Piers Scrimshaw-Wright, Managing Director of the Oxford Science Park, added: “We are delighted to see Evox Therapeutics expanding on the Oxford Science Park as its R&D progresses. It is one of several University of Oxford spin-outs on the Park, cementing our reputation as the place to locate for life sciences business in Oxford.”
